Is there a rationale for bladder cancer screening?

Current Urology Reports

Volumn 9, Issue 5, 2008, Pages 339-341

  Svatek, Robert S ^b   Lotan, Yair ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE; PROSTATE SPECIFIC ANTIGEN; VINBLASTINE;

BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INVASION; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CLINICAL PRACTICE; CYSTOSCOPY; CYTOLOGY; DIAGNOSTIC ACCURACY; DISEASE COURSE; HUMAN; NOTE; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

COST-BENEFIT ANALYSIS; CYSTOSCOPY; EARLY DIAGNOSIS; FALSE POSITIVE REACTIONS; HEALTH CARE COSTS; HUMANS; MASS SCREENING; PREVALENCE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 51949100319     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-008-0058-4     Document Type: Note

References (19)

1. Messing EM, Young TB, Hunt VB, et al.: Hematuria home screening: repeat testing results. J Urol 1995, 154:57-61.
2. Messing EM, Young TB, Hunt VB, et al.: Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology 1995, 45:387-396; discussion 396-397.
3. Britton JP, Dowell AC, Whelan P, Harris CM: A community study of bladder cancer screening by the detection of occult urinary bleeding. J Urol 1992, 148:788-790.
4. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
5. Sternberg CN, Yagoda A, Scher HI, et al.: Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985, 133:403-407.
6. American College of Surgeons: Commission on Cancer National Cancer Database. Available at http://www.facs.org/cancer/ncdb/index.html. Accessed April 23, 2008.
7. Paez A, Coba JM, Murillo N, et al.: Reliability of the routine cytological diagnosis in bladder cancer. Eur Urol 1999, 35:228-232.
8. Raitanen MP, Aine R, Rintala E, et al.: Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol 2002, 41:284-289.
9. Nabi G, Greene DR, O'Donnell M: How important is urinary cytology in the diagnosis of urological malignancies? Eur Urol 2003, 43:632-636.
10. Lotan Y, Roehrborn CG: Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 2003, 61:109-118.
11. Chan EC: Promoting an ethical approach to unproven screening imaging tests. J Am Coll Radiol 2005, 2:311-320.
12. Chan EC, Vernon SW, O'Donnell FT, et al.: Informed consent for cancer screening with prostate-specific antigen: how well are men getting the message? Am J Public Health 2003, 93:779-785.
13. Malm HM: Medical screening and the value of early detection. When unwarranted faith leads to unethical recommendations. Hastings Cent Rep 1999, 29:26-37.
14. National Cancer Institute: NCI cancer screening overview. Available at http://www.cancer.gov/cancerinfo/pdq/screening/overview. Accessed April 23, 2008.
15. Messing EM, Madeb R, Young T, et al.: Long-term outcome of hematuria home screening for bladder cancer in men. Cancer 2006, 107:2173-2179.
16. Mayfield MP, Whelan P: Bladder tumours detected on screening: results at 7 years. Br J Urol 1998, 82:825-828.
17. Wu XR: Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 2005, 5:713-725.
18. Lotan Y, Svatek RS, Sagalowsky Al: Should we screen for bladder cancer in a high-risk population?: a cost per life-year saved analysis. Cancer 2006, 107:982-990.
19. Wu X, Lin J, Grossman HB, et al.: Projecting individualized probabilities of developing bladder cancer in white individuals. J Clin Oncol 2007, 25:4974-4981.